One of our objectives is to provide you with the information you need to best understand how we're working to provide a healthier population and improved healthcare system. You can use our 2014 reporting data below to compare us to other participating ACOs or compare our performance from year to year. To view more current data, visit our Clinical Quality page.
2014 Reporting Period - Physician's Healthcare Collaborative Quality Measure Results and Comparisons
For additional historical data, see our 2013, 2015, 2016, 2017, and 2018 results.
Measure Number | Measure Name | ACO Performance Rate | Mean Performance Rate (SSP ACOs) |
---|---|---|---|
ACO-1 2 | Getting Timely Care, Appointments, and Information | 74.62 | 80.13 |
ACO-2 2 | How Well Your Doctors Communicate | 91.38 | 92.39 |
ACO-3 2 | Patients’ Rating of Doctor | 91.03 | 91.58 |
ACO-4 2 | Access to Specialists | 84.77 | 83.97 |
ACO-5 2 | Health Promotion and Education | 61.43 | 58.29 |
ACO-6 2 | Shared Decision Making | 75.21 | 74.60 |
ACO-7 2 | Health Status/Functional Status | 72.51 | 71.10 |
ACO-8 1 | Risk Standardized, All Condition Readmission | 14.62 | 15.15 |
ACO-9 1 | ASC Admissions: COPD or Asthma in Older Adults | 0.87 | 1.08 |
ACO-10 1 | ASC Admission: HF | 1.12 | 1.19 |
ACO-11 2 | Percent of Primary Care Providers Who Successfully Attested for the EHR Incentive Program Incentive Payment | 86.49 | 76.71 |
ACO-12 2 | Medication Reconciliation | 53.57 | 82.61 |
ACO-13 2 | Falls: Screening for Fall Risk | 63.26 | 45.60 |
ACO-14 2 | Influenza Immunization | 69.90 | 57.51 |
ACO-15 2 | Pneumococcal Vaccination | 81.35 | 55.03 |
ACO-16 2 | Adult Weight Screening and Follow-up | 58.23 | 66.75 |
ACO-17 2 | Tobacco Use Assessment and Cessation Intervention | 95.88 | 86.79 |
ACO-18 2 | Depression Screening | 41.85 | 39.27 |
ACO-19 2 | Colorectal Cancer Screening | 82.28 | 56.14 |
ACO-20 2 | Mammography Screening | 87.35 | 61.41 |
ACO-21 2 | Proportion of Adults who had blood pressure screened in past 2 years | 43.20 | 60.24 |
ACO-22* 2 | Hemoglobin A1c Control (HbA1c) (<8 percent) | 78.14 | Diabetes composite provided only |
ACO-23* 2 | Low Density Lipoprotein (LDL) (< 100 mg/dL) | 70.00 | Diabetes composite provided only |
ACO-24* 2 | Blood Pressure (BP) < 140/90 | 73.02 | Diabetes composite provided only |
ACO-25* 2 | Tobacco Non-Use | 83.49 | Diabetes composite provided only |
ACO-26* 2 | Aspirin Use | 76.47 | Diabetes composite provided only |
ACO-27 1 | Percent of beneficiaries with diabetes whose HbA1c in poor control (>9 percent) | 9.07 | 20.35 |
ACO-28 2 | Percent of beneficiaries with hypertension whose BP < 140/90 | 70.47 | 68.02 |
ACO-29 2 | Percent of beneficiaries with IVD with complete lipid profile and LDL control < 100mg/dl | 71.39 | 57.29 |
ACO-30 2 | Percent of beneficiaries who use Aspirin or other antithrombotic | 84.13 | 80.79 |
ACO-31 2 | Beta-Blocker Therapy for LVSD | 83.74 | 82.71 |
ACO-32* 2 | Drug Therapy for Lowering LDL-Cholesterol | 80.82 | CAD composite provided only |
ACO-33* 2 | (ACE) Inhibitor or (ARB) Therapy for Patients with CAD and Diabetes and/or (LVSD) | 72.15 | CAD composite provided only |
1 The lower the percentage the better the performance.
2 The higher the percentage the better the performance.
* - Measure is part of either the Diabetes Composite measure or the Coronary Artery Disease Composite measure